Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Aktis Oncology, Inc.

Ticker
AKTS
Sector
Industry
Report date
November 15, 2026
Valye AI Score

63

High visibility
Recent developments
Recent developments summary

Recent developments for Aktis Oncology include analyst coverage initiation, FDA Fast Track designation for AKY-1189, clinical data presentation plans, and IPO completion. The company maintains strong liquidity and is focused on advancing its oncology pipeline.

Recent developments:
  • William Blair initiated coverage of Aktis Oncology with an outperform recommendation in April 2026, indicating positive analyst sentiment toward the company [N6].
  • Aktis Oncology's AKY-1189 received FDA Fast Track designation in February 2026, supporting expedited development and review [N1].
  • The company announced plans to present clinical imaging and dosimetry data for AKY-2519 in treating metastatic castration-resistant prostate cancer next month, highlighting ongoing clinical progress [N7].
  • Aktis Oncology completed an upsized initial public offering in January 2026, including full exercise of underwriters’ option to purchase additional shares, providing capital for operations [N1].
  • Recent news discusses potential upside and near-term milestones, reflecting market interest and clinical development focus [N2][N3][N4].
Overview

Aktis Oncology, Inc. operates as a clinical-stage biotechnology company focused on oncology drug development. Its pipeline includes AKY-2519, targeting metastatic castration-resistant prostate cancer, and AKY-1189, which has received FDA Fast Track designation. The company completed an upsized IPO in early 2026 and has ongoing clinical milestones, including upcoming presentations of clinical imaging and dosimetry data. Aktis Oncology has attracted analyst coverage and investor interest, with recent reports highlighting potential upside and near-term catalysts. Financially, the company maintains strong liquidity with substantial cash reserves and a high current ratio, supporting its clinical development activities.

Executive summary

Aktis Oncology, Inc. is a clinical-stage oncology company developing novel cancer therapies with multiple drug candidates in clinical trials, including AKY-2519 and AKY-1189, the latter having FDA Fast Track designation. The company reported $3.9 million in revenue and a net loss of $29.9 million for Q3 2026, with strong liquidity evidenced by $68.3 million in cash and a current ratio of 14.22 as of September 30, 2026, according to its latest 10-Q filing. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for AKTS

Bull case model:

The bull case for Aktis Oncology centers on successful clinical development of its drug candidates, particularly AKY-2519 and AKY-1189, which could lead to regulatory approvals and commercialization. The FDA Fast Track designation for AKY-1189 supports potential accelerated development. Positive clinical data presentations and analyst coverage with outperform recommendations highlight investor interest and potential valuation upside. Strong liquidity provides runway for ongoing trials and corporate activities.

Bear case model:

The bear case involves risks common to clinical-stage biotech companies, including clinical trial failures, regulatory setbacks, and high cash burn leading to dilution or financing challenges. The company reported a net loss of $29.9 million in Q3 2026, reflecting ongoing expenses without profitability. Market volatility and competitive pressures in oncology drug development may also impact the company's prospects. Additionally, lack of disclosed sector and industry classification may reflect limited public information on broader business context.

Moat:

Aktis Oncology's moat is primarily based on its proprietary oncology drug candidates in clinical development and regulatory designations such as the FDA Fast Track for AKY-1189, which may facilitate expedited development and review. The company's focus on novel therapies for difficult-to-treat cancers and its clinical data generation efforts contribute to its competitive positioning. However, as a clinical-stage biotech firm, it faces typical industry risks including clinical trial outcomes, regulatory approvals, and capital requirements.

Risks overview
Risks summary
The primary risk for Aktis Oncology is the uncertainty inherent in clinical development and regulatory approval processes, combined with financial sustainability challenges typical of clinical-stage biotech companies.
Risks details:

• Clinical Development Risk: The success of Aktis Oncology depends on positive clinical trial outcomes for its drug candidates, which are inherently uncertain and may delay or prevent regulatory approvals.
• Regulatory Risk: Regulatory agencies may require additional data or deny approvals, impacting the company's ability to commercialize its therapies.
• Financial Risk: The company is currently operating at a net loss with significant cash burn, requiring continued access to capital markets or partnerships to fund operations.
• Market and Competitive Risk: Competition in oncology drug development is intense, and alternative therapies may limit market opportunities for Aktis Oncology's products.

FINAL FORECAST FOR AKTS

Final take one line
Aktis Oncology is a clinical-stage biotech company with moderate visibility driven by its oncology pipeline, regulatory designations, and solid liquidity.
Final take 12 to 24 month view

Business trends: Continued clinical development of oncology drug candidates with regulatory designations and analyst coverage highlighting potential value.
Execution milestones: Presentation of clinical data for AKY-2519, advancement of FDA Fast Track designated AKY-1189, and capital deployment from IPO proceeds.
Key risks: Clinical trial and regulatory uncertainties, financial sustainability due to ongoing net losses, and competitive pressures in oncology therapeutics.

Valye AI Visibility Research Score

High visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

63
LLM visibility overview
LLM Visibility known facts
  • Aktis Oncology, Inc. is a clinical-stage oncology company focused on developing novel cancer therapies.
  • The company has multiple drug candidates in clinical development, including AKY-2519 for metastatic castration-resistant prostate cancer (MCRPC) and AKY-1189, which has received FDA Fast Track designation.
  • Aktis Oncology reported revenue of $3.905 million for the quarter ending September 30, 2026, with a net loss of $29.939 million and basic and diluted EPS of -$0.54 per share as per its 10-Q filing dated November 12, 2026.
  • As of September 30, 2026, the company had cash and cash equivalents of approximately $68.3 million and current assets of about $499.9 million, with current liabilities of $35.16 million, resulting in a strong current ratio of 14.22 and a cash ratio of 1.94, indicating solid liquidity.
  • Aktis Oncology completed an upsized initial public offering in January 2026, with full exercise of underwriters’ option to purchase additional shares.
  • The company has upcoming clinical milestones including presenting clinical imaging and dosimetry data for AKY-2519 in treating MCRPC.
  • William Blair initiated coverage of Aktis Oncology with an outperform recommendation in April 2026.
  • Aktis Oncology's AKY-1189 received FDA Fast Track designation in February 2026.
  • Recent news highlights include analyst discussions on potential upside and near-term clinical milestones.
  • No sector or industry classification is explicitly disclosed in the available data.
  • Aktis Oncology is distinct from Akoustis Technologies, which recently initiated bankruptcy for strategic asset sale, a separate entity with ticker AKTS but unrelated business.
Sources
Sources - Context summary

Generated 2026-11-15

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-11-12 | 10-Q
Sources - News headlines
  • N1 | 2026-11-15 | www.nasdaq.com | Akoustis Technologies Initiates Bankruptcy for Strategic Asset Sale | https://www.nasdaq.com/articles/akoustis-technologies-initiates-bankruptcy-strategic-asset-sale
  • N2 | 2026-11-11 | www.nasdaq.com | Does Aktis (AKTS) Have the Potential to Rally 105.62% as Wall Street Analysts Expect? | https://www.nasdaq.com/articles/does-aktis-akts-have-potential-rally-10562-wall-street-analysts-expect
  • N3 | 2026-11-02 | www.nasdaq.com | Aktis Oncology Enters Oversold Territory (AKTS) | https://www.nasdaq.com/articles/aktis-oncology-enters-oversold-territory-akts
  • N4 | 2026-08-20 | www.nasdaq.com | Aktis Oncology Slides: What Is The Buzz, Near-Term Milestones, Wedbush View And More | https://www.nasdaq.com/articles/aktis-oncology-slides-what-buzz-near-term-milestones-wedbush-view-and-more
  • N5 | 2026-06-15 | www.nasdaq.com | Top Biotech Gainers: SNSE Awaits Data In 2H, STTK To Begin Crohn's Trial In Q3, ALMS On Watch | https://www.nasdaq.com/articles/top-biotech-gainers-snse-awaits-data-2h-sttk-begin-crohns-trial-q3-alms-watch
  • N6 | 2026-04-30 | www.nasdaq.com | William Blair Initiates Coverage of Aktis Oncology (AKTS) with Outperform Recommendation | https://www.nasdaq.com/articles/william-blair-initiates-coverage-aktis-oncology-akts-outperform-recommendation
  • N7 | 2026-04-22 | www.nasdaq.com | Aktis To Present Clinical Imaging And Dosimetry Data For AKY-2519 In Treating MCRPC Next Month | https://www.nasdaq.com/articles/aktis-present-clinical-imaging-and-dosimetry-data-aky-2519-treating-mcrpc-next-month
  • N8 | 2026-04-17 | www.nasdaq.com | Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's What You Should Know | https://www.nasdaq.com/articles/wall-street-analysts-predict-7473-upside-aktis-akts-heres-what-you-should-know
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine